Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cholinergic Receptors: Muscarinic01:25

Cholinergic Receptors: Muscarinic

5.9K
The pharmacological actions of acetylcholine are elicited via its binding to two families of cholinergic receptors or cholinoceptors, namely, muscarinic and nicotinic receptors. Muscarinic receptors are G protein-coupled receptors and have five subtypes, M1–M5. All mAChR subtypes are activated by acetylcholine and blocked by the antagonist, atropine. 
The subtypes M1, M3, and M5 couple with the Gq subunit and activate the phospholipase C (PLC) activity, mobilizing intracellular Ca2+....
5.9K
Opioid Receptors: Overview01:22

Opioid Receptors: Overview

6.3K
Opioid receptors, including the mu (μ, MOR), delta (δ, DOR), and kappa (κ, KOR) types, belong to the rhodopsin family of G protein-coupled receptors. These receptors are located throughout the central and peripheral nervous systems and in non-neuronal tissues such as macrophages and astrocytes. Opioid receptor ligands can be categorized into agonists or antagonists. Highly selective agonists include [d-Ala2, MePhe4, Gly(ol)5]-enkephalin or DAMGO for MOR, [D-Pen2,...
6.3K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

4.6K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.6K
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.7K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.7K
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

3.2K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
3.2K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

4.1K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Antioxidant, antimicrobial, and AMPA receptor modulatory activities of selected medicinal plant extracts reveal multitarget pharmacological potential.

Scientific reports·2026
Same author

Enzyme-Targeted Antiproliferative Effects of Novel Indole-Acrylamide Xenobiotics Acting on Cyclooxygenase Pathways.

Journal of xenobiotics·2026
Same author

Tirzepatide and Cardiovascular Outcomes: A Narrative Review of Mechanisms, Efficacy and Implications for Heart Failure Management.

Endocrinology, diabetes & metabolism·2026
Same author

Novel Benzimidazole-Urea Phenylalanine Hybrids as Dual-Acting Antimicrobial and Anticancer Agents: In Silico and Biological Evaluation.

Chemical biology & drug design·2026
Same author

Next-Generation HDAC Inhibitors: Advancing Zinc-Binding Group Design for Enhanced Cancer Therapy.

Cells·2025
Same author

Essential oils from Artemisia judaica, Ruta graveolens and Salvia palaestina with antiradical, cytotoxic and AMPA receptor-modulatory activities.

Scientific reports·2025

Related Experiment Video

Updated: Mar 25, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.4K

Auxiliary TARP Subunits Define AMPA Receptor Pharmacology and Function.

Sosana Bdir1, İrfan Çapan2, Mohammed Hawash3

  • 1Department of Medicine, Faculty of Medicine and Allied Medical Sciences, An-Najah National University, Nablus P400, Palestine.

Journal of Xenobiotics
|March 24, 2026
PubMed
Summary

New dibenzobarrelene compounds negatively modulate AMPA receptor function by altering gating kinetics. These compounds show potential for treating neurological disorders like epilepsy by targeting AMPA receptor activity.

Keywords:
AMPA receptorGluA1GluA1/2TARPγ8dibenzobarrelene

More Related Videos

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K
A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

8.2K

Related Experiment Videos

Last Updated: Mar 25, 2026

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
07:16

Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission

Published on: August 16, 2018

14.4K
A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

9.6K
A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

8.2K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • AMPA-type glutamate receptors mediate fast excitatory neurotransmission in the central nervous system.
  • Dysregulation of AMPA receptor function is linked to neuronal hyperexcitability and epilepsy.
  • Modulating AMPA receptor gating kinetics, particularly in a TARP-dependent and subunit-specific manner, is a potential therapeutic strategy.

Purpose of the Study:

  • To characterize the effects of novel dibenzobarrelene-based heterocycles on AMPA receptor function.
  • To investigate the mechanism of action, including effects on gating kinetics and dependence on auxiliary subunits.
  • To establish a pharmacological framework for developing new epilepsy therapies.

Main Methods:

  • Whole-cell patch-clamp electrophysiology was used to record currents from cells expressing GluA1 or GluA1/2 AMPA receptors.
  • Cells were co-expressed with the TARPγ8 auxiliary subunit to assess its influence.
  • The effects of eight dibenzobarrelene derivatives on glutamate-induced currents, desensitization, and deactivation were measured.

Main Results:

  • All tested compounds suppressed glutamate-induced currents, acting as negative allosteric modulators.
  • The compounds accelerated AMPA receptor desensitization and deactivation kinetics.
  • Co-expression of TARPγ8 partially reduced the inhibitory and kinetic effects of the compounds, but did not abolish them.

Conclusions:

  • Dibenzobarrelene derivatives impair AMPA receptor function through a specific kinetic mechanism.
  • These compounds reduce agonist-bound open states and promote transitions to non-conducting states.
  • The findings provide mechanistic insights into AMPA receptor modulation and its dependence on auxiliary proteins.